17 completed, 11 recruiting, 10 terminated, 3 unknown. 46 Phase 2, 16 Phase 1.
Follow Brain Cancer: new trials by email Literature Review of Brain Cancer trials Research Report on Brain Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma LMP744, Conventional Surgery or Biopsy - Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Phase 1 / Phase 2 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 40 | 2026-07-15 | 2026-10-16 |
| Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII silevertinib in combination with temozolomide, temozolomide (TMZ) - Glioblastoma (GBM), Newly Diagnosed Glioblastoma | Phase 2 | Recruiting | Black Diamond Therapeutics, Inc. | 162 | 2026-05-05 | 2026-11-12 |
| Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma Ruxolitinib, Temozolomide, Radiation Therapy - Glioblastoma, Brain Cancer | Phase 2 | Recruiting | Baptist Health South Florida | 190 | 2025-12-03 | 2026-10-02 |
| Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial Riluzole, Placebo - Breast Cancer, Sarcoma | Phase 2 | Recruiting | University of California, Irvine | 75 | 2024-12-02 | 2026-07-14 |
| TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine - Brain Tumor, Brain Metastases | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 85 | 2024-10-20 | 2024-11-05 |
| Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases | Phase 2 | Completed | Reveal Pharmaceuticals Inc. | 18 | 2024-08-15 | 2025-12-26 |
| SGM-101 in Colorectal Brain Metastases. SGM-101 - Rectal Neoplasms, Rectum Cancer | Phase 2 | Unknown | Leiden University Medical Center | 10 | 2024-01-01 | 2024-05-09 |
| Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Trastuzumab deruxtecan - Brain Cancer, Glioblastoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2023-09-22 | 2026-02-23 |
| Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis 18F-Fluciclovine - Brain Metastases, Brain Cancer | Phase 2 | Recruiting | Baptist Health South Florida | 20 | 2023-01-10 | 2025-12-01 |
| Pembro+Chemo in Brain Mets Pembrolizumab, Nab paclitaxel, Paclitaxel - Lung Cancer, Lung Cancer Metastatic | Phase 2 | Terminated | John L. Villano, MD, PhD | 3 | 2022-05-19 | 2025-10-31 |
| Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases Stereotactic Radiation, AGuIX gadolinium-based nanoparticles, Placebo - Brain Cancer, Brain Metastases | Phase 2 | Recruiting | Brigham and Women's Hospital | 134 | 2021-09-15 | 2026-09-09 |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors ST101, Temozolomide, Radiation - Glioblastoma, Melanoma Stage IV | Phase 1 / Phase 2 | Active not recruiting | Sapience Therapeutics | 125 | 2020-07-01 | 2026-02-09 |
| Single vs Multi-fraction SRS Patients on Immunotherapy Radiosurgery Single Treatment, Radiosurgery Three Treatments - Brain Cancer, Brain Metastases | Phase 2 | Withdrawn | University of Chicago | 2020-06-29 | 2023-08-28 | |
| Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas Nivolumab - High Grade Glioma, Brain Cancer | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 43 | 2019-07-30 | 2024-04-02 |
| T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery T-DM1, TMZ - Breast Cancer, Brain Metastasis | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 12 | 2018-04-18 | 2023-10-11 |
| Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression VAL-083 (Dianhydrogalactitol) - Glioma, Glioblastoma | Phase 2 | Completed | Kintara Therapeutics, Inc. | 29 | 2017-12-17 | 2025-09-04 |
| Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®) - Glioblastoma, Brain Cancer | Phase 1 / Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 78 | 2017-10-12 | 2017-11-06 |
| Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Capecitabine, Temozolomide - Glioblastoma Multiforme (GBM), Glioblastoma | Phase 1 / Phase 2 | Recruiting | Northwell Health | 67 | 2017-06-13 | 2026-06-01 |
| Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting VAL-083, Dianhydrogalactitol - Glioma, Glioblastoma | Phase 2 | Completed | Kintara Therapeutics, Inc. | 118 | 2017-01-20 | 2025-08-29 |
| Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects DNX-2401, pembrolizumab - Brain Cancer, Brain Neoplasm | Phase 2 | Completed | DNAtrix, Inc. | 49 | 2016-10-06 | 2021-07-15 |
Showing 20 of 46. Sign in to see all of them.
Brain Neoplasms (46) · Glioblastoma (24) · Glioma (18) · Neoplasms (8) · Breast Neoplasms (5) · Lung Neoplasms (5) · Gliosarcoma (4) · Astrocytoma (3) · Colorectal Neoplasms (3) · Melanoma (3) · Meningioma (3) · Central Nervous System Neoplasms (2) · Gastrointestinal Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms, Nerve Tissue (2)
Neoplasms by Site (46) · Nervous System Neoplasms (46) · Brain Diseases (45) · Central Nervous System Diseases (45) · Nervous System Diseases (45) · Central Nervous System Neoplasms (44) · Neoplasms (38) · Neoplasms by Histologic Type (34) · Neoplasms, Germ Cell and Embryonal (33) · Neoplasms, Nerve Tissue (32) · Neuroectodermal Tumors (32) · Neoplasms, Glandular and Epithelial (31) · Neoplasms, Neuroepithelial (30) · Astrocytoma (21) · Glioma (13)
Temozolomide (9) · Radiotherapy (5) · Bevacizumab (4) · Dianhydrogalactitol (3) · pembrolizumab (3) · Aminolevulinic Acid (2) · Capecitabine (2) · Cyclophosphamide (2) · Erlotinib Hydrochloride (2) · Lomustine (2) · Radiation (2) · fludarabine (2) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · Antibodies, Monoclonal (1)
M.D. Anderson Cancer Center (9) · Memorial Sloan Kettering Cancer Center (4) · Kintara Therapeutics, Inc. (3) · Northwell Health (3) · Assistance Publique - Hôpitaux de Paris (2) · Baptist Health South Florida (2) · National Cancer Institute (NCI) (2) · AHS Cancer Control Alberta (1) · Baylor College of Medicine (1) · Black Diamond Therapeutics, Inc. (1) · Brigham and Women's Hospital (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Constantinos Hadjipanayis (1) · DNAtrix, Inc. (1) · David Piccioni, M.D., Ph.D (1)
United States (37) · Canada (3) · France (3) · China (2) · United Kingdom (2) · Netherlands (1)
John Boockvar, MD (2) · John DeGroot, MD (2) · Abi Vainstein-Haras, MD (1) · Alexandre Chan, PharmD, MPH (1) · Antonio Omuro, MD (1) · Ayal Aizer, MD, MHS (1) · Barbara O'Brien, M.D. (1) · Caroline Chung, MD (1) · Charles A. Conrad, MD (1) · Charles Conrad, MD (1) · Chen Zhong-ping, M.D., Ph.D. (1) · Costas Hadjipanayis, MD, PhD (1) · David Piccioni, M.D., Ph.D. (1)
PMID 22780919, PMID 23341526, PMID 23545055, PMID 26428319, PMID 32270710, PMID 36705597, PMID 37188783, PMID 38537315, PMID 38796495, PMID 41385182
2015 (1), 2017 (1), P50NS020023 (1), R01CA176659 (1), R01CA187202 (1), R01NS052274 (1), R21CA186169 (1), R44CA261240 (1)